Analyzing Madrigal Pharmaceuticals' Fundamental Performance Before Investing

By Scott Lee • Thursday, July 30 10:45 • Permanent Link

Madrigal Pharmaceuticals sank -14.2% today, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Madrigal Pharmaceuticals has moved 80.8% over the last year, and the S&P 500 logged a change of 15.4%
MDGL has an average analyst rating of buy and is -30.96% away from its mean target price of $680.0 per share
Its trailing earnings per share (EPS) is $-13.73
Madrigal Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -34.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $12.38 and its forward P/E ratio is 37.9
The company has a Price to Book (P/B) ratio of 19.9 in contrast to the S&P 500's average ratio of 4.74
Madrigal Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
The company has a free cash flow of $-156403504, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.